Launch of Hong Kong facility & pipeline expansion

Investor Highlights:

- **Strategic gateway into the US$5.36 billion Asia-Pacific point-of-care testing market[1]**
  The facility embeds Nexsen within the Asia-Pacific healthcare ecosystem, positioning the Company closer to target populations, clinicians, regulators and distribution partners as it advances towards regional market entry
- **Expanded diagnostics pipeline into two large unmet healthcare markets**
  The facility will advance Nexsen's existing portfolio and support two new programs targeting Traumatic Brain Injury, which affects an estimated 69 million people globally each year[2], and neonatal sepsis, a leading cause of newborn mortality worldwide
- **Building an integrated Asia-Pacific R&D capability**
  Together with the Company's Joint Research Facility with Universiti Malaya, the Hong Kong facility further strengthens Nexsen's regional R&D capability through a dedicated team of full-time researchers and collaborations with leading researchers across four Hong Kong universities

Nexsen Limited (ASX:NXN) ("Nexsen" or "the Company"), an emerging leader in rapid point-of-care diagnostics, is pleased to announce the establishment of its next-generation research and development facility in Hong Kong, representing a significant milestone in the Company's Asia-Pacific growth strategy.

The new facility will become Nexsen's principal laboratory for Asia, supporting the development, clinical validation and future commercialisation of rapid diagnostic technologies for some of the region's largest healthcare challenges. The Company also continues to evaluate future manufacturing expansion opportunities from Hong Kong as demand across Asian markets grows.

The laboratory complements Nexsen's existing Australian operations, creating an integrated Australia-Hong Kong innovation platform that combines Australian scientific capability with direct access to one of Asia's leading healthcare and life sciences ecosystems.



Nexsen Hong Kong Scientific Team, Dr Zhang Xin and Dr YE Ziyun, with Professor Shekhar Kumta.

Nexsen Hong Kong Staff with Managing Director Mark Muzzin

[1] https://www.marketdataforecast.com/market-reports/asia-pacific-point-of-care-diagnostics-market
[2] https://www.emro.who.int/media/news/remarks-by-dr-hanan-balkhy-who-regional-director-wha79-high-level-global-event-recognizing-traumatic-brain-injury-as-a-notifiable-chronic-condition.html?utm_source=chatgpt.com

Managing Director, Mark Muzzin, commented:

"The establishment of our Hong Kong facility is an important step in building Nexsen's presence across Asia and expanding the reach of our rapid diagnostics platform. By creating a dedicated local R&D base, we can work more closely with our university, clinical and healthcare partners, bringing together the expertise, patient access and translational capability already established through Nexsen Hong Kong.

"This positions us to advance our existing portfolio, develop new programs in Traumatic Brain Injury and neonatal sepsis, and move innovation closer to the populations, regulators and healthcare markets we intend to serve."

Strategic gateway into the $5.36 Billion Asia-Pacific point-of-care testing market

Hong Kong has been selected as the location for Nexsen's Asian physical presence to its globally recognised research capability, internationally accredited healthcare system and strategic position as a gateway into major Asian healthcare markets.

The establishment of the facility builds on the Company's previously announced Hong Kong expansion, including the award of a HK$6 million Ignite grant, providing both funding support and a pathway to pursue additional non-dilutive grant opportunities within Hong Kong's innovation ecosystem.

The facility also positions Nexsen closer to future commercial markets, regulatory agencies and distribution networks across Asia, supporting the Company's long-term commercial strategy.

Expanding Nexsen's diagnostic pipeline

The Hong Kong laboratory will support ongoing development across Nexsen's existing diagnostics portfolio, including:

- Group B Streptococcus
- Acute Kidney Injury
- Chronic Kidney Disease
- Bovine Mastitis
- Biosecurity and Food Safety

In addition, the Company has expanded research into two significant new diagnostic programs:

- Traumatic Brain Injury (TBI), where rapid diagnosis is critical to guiding treatment decisions and improving patient outcomes. TBI affects an estimated 69 million people globally each year, yet early diagnosis remains a significant clinical challenge, particularly in emergency care settings where rapid decision-making is essential.
- Neonatal Sepsis Spectroscopy, targeting one of the leading causes of newborn mortality worldwide. An estimated 2.3 million newborns die each year, with sepsis accounting for approximately 15% of newborn deaths globally[3]. Early and accurate diagnosis remains a major unmet need, with the World

[3] https://www.who.int/news/item/06-08-2025-who-releases-new-tpp-for-diagnostic-tests-to-detect-serious-bacterial-infections-in-young-infants?utm_source=chatgpt.com

Health Organisation recently identifying improved diagnostics for neonatal sepsis as a global priority to reduce infant deaths and unnecessary antibiotic use.

These programs leverage the specialised clinical expertise and research capability available through Nexsen's Hong Kong collaborations and represent further expansion of the Company's scalable rapid diagnostics platform into globally significant healthcare markets.

The facility will also support ongoing evaluation of additional diagnostic opportunities as the Company continues leveraging its proprietary biosensing platform across new clinical applications.

Building on Nexsen's Asia-Pacific strategy, anchored in Hong Kong

The new facility will provide a physical base for Nexsen's growing network of university, clinical and healthcare partnerships in Hong Kong, enabling closer collaboration across research, product development and clinical validation. The laboratory will be operated by a dedicated local team of full-time Nexsen researchers, establishing permanent on-the-ground R&D capability in Hong Kong and strengthening the Company's ability to manage regional research programs, clinical collaborations and product development activities.

Nexsen Hong Kong has established collaborations with four of Hong Kong's leading universities:

- The University of Hong Kong (HKU), supporting microbiology research and clinical validation of Nexsen's GBS diagnostics.
- The Chinese University of Hong Kong (CUHK), supporting neonatal intensive care, microbiology and neonatal sepsis spectroscopy.
- City University of Hong Kong (CityU), supporting aptamer characterisation and biosensor development.
- Hong Kong Metropolitan University (HKMU), supporting applied research and translational collaboration.

These relationships provide Nexsen with access to specialist expertise, clinical networks and relevant patient populations across multiple areas of its diagnostics pipeline.

The Hong Kong R&D hub will bring these capabilities together within a dedicated local environment, strengthening collaboration and accelerating the translation of research into clinically validated and commercially scalable diagnostics.

It will also complement the Company's UM–Nexsen Joint Research Facility with Universiti Malaya, creating a broader Asia-Pacific innovation network spanning Hong Kong and Malaysia. Together, these facilities strengthen Nexsen's regional research, development and commercialisation capability, while providing access to leading researchers, clinical networks and institutional partners across key Asian markets.

The Hong Kong facility is supported by Nexsen's previously announced HK$6 million Ignite grant, providing non-dilutive funding for the Company's Hong Kong activities.

-ENDS-

ASX release authorised by the Board of Directors.

For more information, please contact:

Corporate Enquiries

e: corporate@nexsen.bio

w: www.nexsen.bio

a: Suite 1005, 4 Bridge Street, Sydney NSW 2000, Australia

Company Secretary

e: sd@nexsen.bio

p: 61 2 9174 5388

About Nexsen Limited (ASX: NXN)

Nexsen is developing a suite of rapid point-of-care diagnostics for conditions that have traditionally depended on delayed laboratory testing. The Company is focused on areas of significant unmet clinical need, where faster diagnosis can improve patient outcomes and reduce pressure on healthcare systems. Nexsen's lead diagnostic is the GBS Rapid Sensor, a rapid point-of-care diagnostic for detecting Group B Streptococcus, addressing a critical unmet need in maternal health. The Company is also developing rapid kidney function diagnostics for Acute Kidney Injury and Chronic Kidney Disease, two conditions that affect more than 850 million people globally and remain underserved by slow, lab-based diagnostics.

With further diagnostics in development across human health, ag-tech and biosecurity, Nexsen aims to become a global leader in rapid point-of-care diagnostics, delivering on its mission to ensure every person benefits from a Nexsen test at some point in their life.

Forward Looking Statements Disclaimer

Forward looking statements are typically identified by the use of forward looking terminology such as 'aims',' believes',' expects',' may',' will',' could',' should',' seeks',' intends',' estimates',' plans',' assumes',' envisages', or the negative thereof or other words of similar meaning. Examples of such forward looking statements include, among others, statements or discussions regarding the Company's business, financial or investment strategies, regulatory and product rollout strategies, estimates of expenditure, present or future plans or events, prospects, growth, objectives for future operations and estimates. Such forward looking statements include matters that are not historical facts and are subject to a number of risks and uncertainties, many of which are beyond the Company's control and all of which are based on the Company's current beliefs, intentions or expectations about future events. Such statements are, by their nature, subject to a number of known and unknown risks, uncertainties, assumptions and other important factors that could cause actual results, performance or achievements to differ materially from any expected future results, performance or achievements expressed or implied, by the forward looking statement.

Neither the Company nor any person gives any representation, assurance or guarantee that the occurrence of the event expressed or implied in any forward looking statements in this document will actually occur and you are cautioned not to place undue reliance on such forward looking statements. Factors that might cause forward looking statements to differ materially from actual results, performance or achievements include, among other things, global economic conditions, economic conditions in jurisdictions in which the Company may operate or invest, credit markets, legislative fiscal and regulatory developments, the effects of continued volatility in markets and exchange rate fluctuations. The forward looking statements contained in this document speak only as of the date this document and each of the Company, respective directors, officers, employees, agents, representatives and/or advisers expressly disclaims any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this document.